Should I buy or sell Compugen stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CGEN shares. View CGEN analyst ratings or view top-rated stocks .

What is Compugen's stock price target for 2024?

2 analysts have issued 1-year price targets for Compugen's stock. Their CGEN share price targets range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 112.8% from the stock's current price. View analysts price targets for CGEN or view top-rated stocks among Wall Street analysts .

How have CGEN shares performed in 2024?

Compugen's stock was trading at $1.98 at the beginning of the year. Since then, CGEN stock has decreased by 5.1% and is now trading at $1.88. View the best growth stocks for 2024 here .

Are investors shorting Compugen?

Compugen saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,090,000 shares, an increase of 11.8% from the March 15th total of 1,870,000 shares. Based on an average daily trading volume, of 651,500 shares, the days-to-cover ratio is presently 3.2 days. View Compugen's Short Interest .

When is Compugen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our CGEN earnings forecast .

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) released its earnings results on Tuesday, March, 5th. The biotechnology company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.01. The biotechnology company earned $33.46 million during the quarter, compared to the consensus estimate of $60 million.

What ETF holds Compugen's stock?

ARK Israel Innovative Technology ETF holds 1,049,308 shares of CGEN stock, representing 2.32% of its portfolio.

What is Anat Cohen-Dayag's approval rating as Compugen's CEO?

2 employees have rated Compugen Chief Executive Officer Anat Cohen-Dayag on Glassdoor.com . Anat Cohen-Dayag has an approval rating of 100% among the company's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Compugen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP) , NVIDIA (NVDA) , Advanced Micro Devices (AMD) , QUALCOMM (QCOM) , AbbVie (ABBV) , Inovio Pharmaceuticals (INO) , Netflix (NFLX) , Gilead Sciences (GILD) and Pfizer (PFE) .

Who are Compugen's major shareholders?

Compugen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Matrix Asset Advisors Inc. NY (0.10%).

How do I buy shares of Compugen?

Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CGEN

Compugen (CGEN) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free CGEN Stock Alerts

$1.88

-0.02 (-1.05%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.83
▼
$1.96
50-Day Range: $1.90
▼
$2.95
52-Week Range: $0.53
▼
$3.03

Volume: 308,846 shs
Average Volume: 642,621 shs
Market Capitalization: $162.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Get Compugen alerts:

Compugen MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 112.8% Upside
$4.00 Price Target
Short Interest: Healthy
2.41% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.79
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From $0.02 to ($0.27) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.32 out of 5 stars

Medical Sector

730th out of 918 stocks

Biological Products, Except Diagnostic Industry

120th out of 149 stocks

3.5

Analyst's Opinion

Consensus Rating
Compugen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Compugen has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.41% of the outstanding shares of Compugen have been sold short.
Short Interest Ratio / Days to Cover
Compugen has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Compugen has recently increased by 11.76%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Compugen does not currently pay a dividend.
Dividend Growth
Compugen does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CGEN.

2.7

News and Social Media Coverage

News Sentiment
Compugen has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Compugen this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for CGEN on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Compugen to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Compugen insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.50% of the stock of Compugen is held by insiders.
Percentage Held by Institutions
Only 12.22% of the stock of Compugen is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Compugen are expected to decrease in the coming year, from $0.02 to ($0.27) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Compugen is -8.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Compugen is -8.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Compugen has a P/B Ratio of 2.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Compugen Stock (NASDAQ:CGEN)

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

CGEN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CGEN Stock News Headlines

April 15, 2024 | stocknews.com

3 Biotech Stocks with Potential Gains - Watch or Buy?

April 13, 2024 | americanbankingnews.com

Compugen (NASDAQ:CGEN) Stock Crosses Above Two Hundred Day Moving Average of $1.63

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 11, 2024 | investing.com

Compugen reports progress on cancer therapy COM503

April 10, 2024 | prnewswire.com

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

April 3, 2024 | finance.yahoo.com

Compugen to Participate in Two Upcoming Investor Conferences

April 2, 2024 | finance.yahoo.com

Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 31% Discount?

March 16, 2024 | markets.businessinsider.com

Truist Financial Reaffirms Their Buy Rating on Compugen (CGEN)

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 11, 2024 | finance.yahoo.com

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy

March 8, 2024 | seekingalpha.com

Compugen Ltd. (CGEN) Q4 2023 Earnings Call Transcript

March 8, 2024 | markets.businessinsider.com

Buy Rating Justified by Compugen’s Positive Clinical Outlook and Financial Stability

March 7, 2024 | finance.yahoo.com

Compugen Ltd. (NASDAQ:CGEN) Q4 2023 Earnings Call Transcript

March 7, 2024 | finanznachrichten.de

Compugen Ltd.: Compugen Reports Fourth Quarter and Full Year 2023 Results

March 6, 2024 | prnewswire.com

Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024

March 5, 2024 | msn.com

CGEN Stock Earnings: Compugen Misses EPS, Beats Revenue for Q4 2023

March 5, 2024 | sfgate.com

Compugen: Q4 Earnings Snapshot

March 5, 2024 | prnewswire.com

Compugen Reports Fourth Quarter and Full Year 2023 Results

March 4, 2024 | benzinga.com

Earnings Preview For Compugen

February 26, 2024 | finance.yahoo.com

Compugen to Present at the Leerink Partners Global Biopharma Conference 2024

February 26, 2024 | prnewswire.com

Compugen to Present at the Leerink Partners Global Biopharma Conference 2024

February 22, 2024 | benzinga.com

Compugen Stock (NASDAQ:CGEN), Short Interest Report

February 22, 2024 | benzinga.com

Compugen Stock (NASDAQ:CGEN) Dividends: History, Yield and Dates

February 21, 2024 | finance.yahoo.com

Compugen (CGEN) is a Great Momentum Stock: Should You Buy?

February 20, 2024 | finance.yahoo.com

Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024

February 20, 2024 | prnewswire.com

Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024

February 16, 2024 | finance.yahoo.com

CGEN Mar 2024 7.500 call

See More Headlines

Receive CGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:CGEN
CUSIP: N/A
CIK: 1119774
Web: www.cgen.com
Phone: (723) 765-8585
Fax: 972-3765-8555
Employees: 68
Year Founded: 1993

Price Target and Rating

Average Stock Price Target: $4.00
High Stock Price Target: $4.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +111.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.22)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 94.50
P/E Growth: N/A
Net Income: $-18,750,000.00
Net Margins: N/A
Pretax Margin: -29.24%
Return on Equity: -30.01%
Return on Assets: -21.41%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.36
Quick Ratio: 4.36

Sales & Book Value

Annual Sales: $33.46 million
Price / Sales: 4.89
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.76 per share
Price / Book: 2.49

Miscellaneous

Outstanding Shares: 86,620,000
Free Float: 78,396,000
Market Cap: $163.71 million
Optionable: Optionable
Beta: 2.63

Social Links

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Anat Cohen-Dayag Ph.D. (Age 57)
CEO, President & Director
Comp: $796.52k
Dr. Zurit Levine Ph.D. (Age 56)
Senior Vice President of Technology Innovation
Comp: $345.7k
Dr. Pierre Ferre Ph.D. (Age 47)
Vice President of Preclinical Development
Comp: $415.1k
Mr. Alberto Sessa (Age 62)
Chief Financial Officer
Dr. Eran Ophir Ph.D. (Age 46)
Chief Scientific Officer
Ms. Yvonne Naughton
Head of Investor Relations & Corporate Communications
Mr. Eran Ben Dor
General Counsel & Corporate Secretary
Ms. Dorit Amitay (Age 56)
Vice President of Human Resources
Dr. Yaron Turpaz M.B.A. (Age 53)
Ph.D., Senior VP & Senior Advisor of Data and Informatics Solutions
Rivka Schwartz
Vice President Research and Discovery

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Compugen stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CGEN shares.
View CGEN analyst ratings or view top-rated stocks.
What is Compugen's stock price target for 2024?: 2 analysts have issued 1-year price targets for Compugen's stock. Their CGEN share price targets range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 112.8% from the stock's current price.
View analysts price targets for CGEN or view top-rated stocks among Wall Street analysts.
How have CGEN shares performed in 2024?: Compugen's stock was trading at $1.98 at the beginning of the year. Since then, CGEN stock has decreased by 5.1% and is now trading at $1.88.
View the best growth stocks for 2024 here.
Are investors shorting Compugen?: Compugen saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,090,000 shares, an increase of 11.8% from the March 15th total of 1,870,000 shares. Based on an average daily trading volume, of 651,500 shares, the days-to-cover ratio is presently 3.2 days.
View Compugen's Short Interest.
When is Compugen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our CGEN earnings forecast.
How were Compugen's earnings last quarter?: Compugen Ltd. (NASDAQ:CGEN) released its earnings results on Tuesday, March, 5th. The biotechnology company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.01. The biotechnology company earned $33.46 million during the quarter, compared to the consensus estimate of $60 million.

What ETF holds Compugen's stock?: ARK Israel Innovative Technology ETF holds 1,049,308 shares of CGEN stock, representing 2.32% of its portfolio.
What is Anat Cohen-Dayag's approval rating as Compugen's CEO?: 2 employees have rated Compugen Chief Executive Officer Anat Cohen-Dayag on Glassdoor.com. Anat Cohen-Dayag has an approval rating of 100% among the company's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Compugen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Netflix (NFLX), Gilead Sciences (GILD) and Pfizer (PFE).
Who are Compugen's major shareholders?: Compugen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Matrix Asset Advisors Inc. NY (0.10%).
How do I buy shares of Compugen?: Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CGEN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Compugen (CGEN) Stock Price, News & Analysis

Compugen MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Compugen Stock (NASDAQ:CGEN)

CGEN Stock Price History

CGEN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

CGEN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™